Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma

European Journal of Cancer

Volumn 41, Issue 18, 2005, Pages 2846-2852

  Bramer, Jos A M ^a,b   Abudu, Adesegun A ^a   Tillman, Roger M ^a   Carter, Simon R ^a   Sumathi, Vaiyapuri P ^a   Grimer, Robert J ^a  

^a ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adult; Alkaline phosphatase; Local recurrence; Osteosarcoma; Prognosis; Response to chemotherapy; Subtype; Survival

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER LOCALIZATION; CANCER PREVENTION; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RETROSPECTIVE STUDY;

ADULT; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 28244456554     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.07.024     Document Type: Article

References (23)

1. M.P. Link, A.M. Goorin, and M. Horowitz Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: updated results of the multi-institutional osteosarcoma study Clin Orthopaed Rel Res 270 1991
2. S.S. Bielack, B. Kempf-Bielack, and G. Delling Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols J Clin Oncol 20 2002 776 790
3. D.B. Glasser, J.M. Lane, and A.G. Huvos Survival, prognosis, and therapeutic response in osteogenic sarcoma: the memorial hospital experience Cancer 69 1992 698 708
4. R.L. Souhami, A.W. Craft, and J.W. Van der Eijken Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup Lancet 350 1997 911 917
5. G. Bacci, S. Ferrari, and F. Bertoni Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: an updated report J Clin Oncol 18 2000 4016 4027
6. A.M. Davis, R.S. Bell, and P.J. Goodwin Prognostic factors in osteosarcoma: a critical review J Clin Oncol 12 1994 423 431
7. G. Bacci, P. Picci, and S. Ferrari Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy Cancer 71 1993 1224 1230
8. G. Bacci, A. Longhi, and S. Ferrari Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute Oncol Rep 9 2002 171 175
9. M.P. Stokkel, M.F. Linthorst, and J.J. Borm A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma J Cancer Res Clin Oncol 128 2002 393 399
10. S. Ferrari, F. Bertoni, and M. Mercuri Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at flie Rizzoli Institute Ann Oncol 12 2001 1145 1150
11. W.P. Thorpe, J.J. Reilly, and S.A. Rosenberg Prognostic significance of alkaline phosphatase measurements in patients with osteogenie sarcoma receiving chemotherapy Cancer 43 1979 2178 2181
12. H. Juergens, C. Kosloff, and A. Nirenberg Prognostic factors in the response of primary osteogenic sarcoma to pre-operative chemotherapy (high-dose methotrexate with citrovorum factor) Natl Cancer Inst Monogr 1981 221 226
13. L. Pochanugool, T. Subhadharaphandou, and M. Dhanachai Prognostic factors among 130 patients with osteosarcoma Clin Orthopaed Rel Res 345 1997
14. V.H. Bramwell, W.P. Steward, and M. Nooij Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study J Clin Oncol 17 1999 3260 3269
15. G. Rosen, B. Caparros, and A.G. Huvos Pre-operative chemotherapy for osteogenic sarcoma: selection of post-operative adjuvant chemotherapy based on the response of the primary tumor to pre-operative chemotherapy Cancer 49 1982 1221 1230
16. CDM Fletcher, KK Unni, and F. Mertens World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone WHO classification of bone tumours 2002 IARC Press Lyon
17. S. Bielack, B. Kempf-Bielack, and D. Schwenzer Neoadjuvant therapy for localized extremity osteosarcoma. Experience of the Cooperative Osteosarcoma Study Group COSS with 925 patients Klinische Padiatrie 211 1999 260 270
18. H.J. Van der Woude, J.L. Bloem, and K.L. Verstraete Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery AJR Am J Roentgenol 165 1995 593 598
19. J.A. Bramer, F.M. Gubler, and M. Maas Colour Doppler ultrasound predicts chemotherapy response, but not survival in paediatric osteosarcoma Pediatr Radiol 34 2004 614 619
20. M.K. Schwartz Biochemical procedures as aids in diagnosis of different forms of cancer Ann Clin Lab Sci 4 1974 95 103
21. I. Singh, K.Y. Tsang, and G.D. Ludwig Alkaline phosphatase and ultrastructural alterations in human osteosarcoma cells in tissue culture Eur Surg Res 6 1974 247 263
22. G. Bacci, S. Ferrari, and N. Delepine Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients pre-operatively treated with high-dose methotrexate, doxorubicin, and cisplatin J Clin Oncol 16 1998 658 663
23. E.I. Hauben, S. Weeden, and J. Pringle Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup Eur J Cancer 38 2002 1218 1225